Drug General Information |
Drug ID |
D0OX0V
|
Former ID |
DNC005883
|
Drug Name |
2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H14N4S
|
Canonical SMILES |
CCSC1=CC=CC2=C1N=C(N2)C3=NC4=CC=CC=C4N=C3
|
InChI |
1S/C17H14N4S/c1-2-22-15-9-5-8-13-16(15)21-17(20-13)14-10-18-11-6-3-4-7-12(11)19-14/h3-10H,2H2,1H3,(H,20,21)
|
InChIKey |
IHVQPVYBIZVMSJ-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A3 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
NGF-independant TRKA activation
|
Adenosine P1 receptors
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
Monoamine Transport
|
GPCRs, Class A Rhodopsin-like
|
NGF signalling via TRKA from the plasma membrane
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
GPCRs, Other
|
References |
REF 1 | J Med Chem. 2005 Dec 29;48(26):8253-60.2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. |